PNPLA3 and metabolic dysfunction-associated steatotic liver disease: ,96 Not only does this human genetics–informed finding expand our understanding of MASLD progression, but it also has potentially significant implications for the clinical implementation of PNPLA3-targeted therapies in the future, as these will likely need to be delivered to multiple cell types, including stellate cells, rather than only to hepatocytes.